Natriumphosphat Braun

Disodium Phosphate Dodecahydrate and Sodium Dihydrogen Phosphate Dihydrate, the active ingredients in Natriumphosphat Braun, are electrolyte solutions presented as a sterile solution for injection for intravenous use. It helps replenish phosphate stores and contributes to extracellular fluid buffering, supporting electrolyte balance in patients who require fluid therapy. GNH USA supplies Natriumphosphat Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Natriumphosphat Braun is an intravenous electrolyte solution used in clinical situations that require phosphate supplementation or acid‑base management. - Hypophosphatemia: restores serum phosphate levels in patients with low phosphate concentrations. - Metabolic acidosis: provides phosphate ions that act as buffers to help correct acid‑base disturbances. - Renal dialysis: supplies phosphate during dialysis procedures to maintain electrolyte equilibrium. - Peri‑operative fluid management: supports electrolyte balance during major surgery when large fluid shifts occur.

Adverse reactions may occur with any intravenous electrolyte preparation. Monitoring and prompt management are essential.

Common Side Effects: - Hyperphosphatemia: elevated serum phosphate levels. - Hypocalcemia: reduced calcium due to phosphate binding. - Hypernatremia: increased sodium concentration. - Local irritation at the infusion site. - Nausea or mild gastrointestinal discomfort. - Transient fever or chills.

Serious or Rare Side Effects: - Severe electrolyte imbalance leading to cardiac arrhythmia. - Anaphylactic or severe hypersensitivity reaction. - Thrombophlebitis or vein inflammation. - Metabolic alkalosis from excessive buffering. - Acute renal failure in susceptible patients. - Life‑threatening hypotension due to rapid infusion.

Use of Natriumphosphat Braun requires careful clinical assessment and monitoring. - Baseline assessment: obtain serum phosphate, calcium, sodium, and renal function before initiation. - Ongoing monitoring: check electrolyte levels and acid‑base status regularly during therapy. - Renal impairment: adjust infusion rate and total dose in patients with reduced kidney function. - Infusion speed: avoid rapid bolus administration to reduce risk of cardiovascular instability. - Caution with calcium: do not co‑administer calcium‑containing solutions through the same line. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Phosphate solutions can interact with other medications, affecting safety or efficacy.

Major Interactions (Avoid): - Calcium salts: precipitation can occur, leading to catheter blockage. - Magnesium or aluminum‑containing antacids: risk of insoluble complexes. - High‑dose vitamin D: may exacerbate hyperphosphatemia.

Moderate Interactions (Monitor Closely): - Loop diuretics: increase renal phosphate loss, requiring dose adjustment. - NSAIDs: may impair renal clearance of phosphate. - Corticosteroids: can alter calcium‑phosphate balance. - Insulin therapy: shifts phosphate intracellularly, potentially lowering serum levels.